ASCO: Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors
ABSTRACTS: 3000 and 3005
Two early-phase clinical trials presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center demonstrate promising responses and safety profiles in heavily pretreated patients with advanced solid tumors. The studies were featured in an oral abstract session highlighting the development of new molecularly targeted...
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
ABSTRACTS: 6504, 6507
Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two...
ASCO: MD Anderson’s Sharon Giordano and Richard Gorlick honored as 2024 Special Awards Recipients
In honor of their outstanding contributions to the field of oncology, two researchers from The University of MD Anderson Cancer Center will...
MD Anderson Research Highlights: ASCO 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
This special edition features presentations by MD Anderson researchers at the 2024 American Society...
MD Anderson Research Highlights for May 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
End-of-life systemic treatment for patients with advanced cancers does not improve survival
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to...
MD Anderson Research Highlights for May 8, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Increasing doses of varenicline or nicotine replacement helps persistent smokers quit
For most smokers, quitting on the first attempt is likely to be unsuccessful, but a new study from The University of Texas MD Anderson Cancer...
MD Anderson researcher Sharon Dent elected to prestigious National Academy of Sciences
Sharon Dent, Ph.D., professor of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, has been...
MD Anderson and Pan American Health Organization join forces to support cancer prevention and control in the Americas
The University of Texas MD Anderson Cancer Center and the Pan American Health Organization (PAHO) today announced the signing of an agreement...